- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT00853099
A Study of Adalimumab in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis
A Multi-Center, Randomized, Double-Blind, Placebo-controlled Study of Adalimumab in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis.
Обзор исследования
Статус
Условия
Вмешательство/лечение
Подробное описание
Тип исследования
Регистрация (Действительный)
Фаза
- Фаза 3
Контакты и местонахождение
Места учебы
-
-
-
Asahikawa, Япония
- Site Reference ID/Investigator# 47136
-
Chiba, Япония
- Site Reference ID/Investigator# 47159
-
Chikushino, Япония
- Site Reference ID/Investigator# 47183
-
Fukuoka-shi, Япония
- Site Reference ID/Investigator# 47135
-
Fukuoka-shi, Япония
- Site Reference ID/Investigator# 47182
-
Hamamatsu, Япония
- Site Reference ID/Investigator# 47124
-
Hirakata-shi, Япония
- Site Reference ID/Investigator# 47130
-
Hirosaki, Япония
- Site Reference ID/Investigator# 47103
-
Hiroshima, Япония
- Site Reference ID/Investigator# 47178
-
Hiroshima, Япония
- Site Reference ID/Investigator# 47179
-
Hiroshima-shi, Япония
- Site Reference ID/Investigator# 47131
-
Izumo, Япония
- Site Reference ID/Investigator# 47176
-
Kagoshima, Япония
- Site Reference ID/Investigator# 47226
-
Kanazawa-shi, Япония
- Site Reference ID/Investigator# 47123
-
Kashiwa, Япония
- Site Reference ID/Investigator# 47160
-
Kawagoe, Япония
- Site Reference ID/Investigator# 47108
-
Koshigaya, Япония
- Site Reference ID/Investigator# 47107
-
Kurume, Япония
- Site Reference ID/Investigator# 47181
-
Kurume, Япония
- Site Reference ID/Investigator# 47222
-
Kurume, Япония
- Site Reference ID/Investigator# 47223
-
Kyoto, Япония
- Site Reference ID/Investigator# 47127
-
Kyoto, Япония
- Site Reference ID/Investigator# 47172
-
Kyoto-shi, Япония
- Site Reference ID/Investigator# 47170
-
Kyoto-shi, Япония
- Site Reference ID/Investigator# 47171
-
Matsuyama-shi, Япония
- Site Reference ID/Investigator# 47134
-
Miyazaki, Япония
- Site Reference ID/Investigator# 47225
-
Morioka-shi, Япония
- Site Reference ID/Investigator# 47138
-
Nagakute-shi, Япония
- Site Reference ID/Investigator# 47168
-
Nagoya-shi, Япония
- Site Reference ID/Investigator# 47125
-
Nagoya-shi, Япония
- Site Reference ID/Investigator# 47126
-
Nagoya-shi, Япония
- Site Reference ID/Investigator# 47166
-
Niigata-shi, Япония
- Site Reference ID/Investigator# 47122
-
Nishihara, Япония
- Site Reference ID/Investigator# 47227
-
Nishinomiya-shi, Япония
- Site Reference ID/Investigator# 47174
-
Oita, Япония
- Site Reference ID/Investigator# 47224
-
Okayama-shi, Япония
- Site Reference ID/Investigator# 47177
-
Okinawa, Япония
- Site Reference ID/Investigator# 47228
-
Osaka, Япония
- Site Reference ID/Investigator# 47129
-
Osaka-shi, Япония
- Site Reference ID/Investigator# 47128
-
Otsu-shi, Япония
- Site Reference ID/Investigator# 47169
-
Sagamihara-shi, Япония
- Site Reference ID/Investigator# 47118
-
Saitama-shi, Япония
- Site Reference ID/Investigator# 47158
-
Sakura, Япония
- Site Reference ID/Investigator# 47109
-
Sapporo, Япония
- Site Reference ID/Investigator# 47137
-
Sapporo-shi, Япония
- Site Reference ID/Investigator# 15853
-
Sendai-shi, Япония
- Site Reference ID/Investigator# 47104
-
Sendai-shi, Япония
- Site Reference ID/Investigator# 47147
-
Susaki-shi, Япония
- Site Reference ID/Investigator# 47180
-
Takamatsu, Япония
- Site Reference ID/Investigator# 47133
-
Takatsuki-shi, Япония
- Site Reference ID/Investigator# 47173
-
Tokorozawa-shi, Япония
- Site Reference ID/Investigator# 47106
-
Tokushima, Япония
- Site Reference ID/Investigator# 47132
-
Tokyo, Япония
- Site Reference ID/Investigator# 47110
-
Tokyo, Япония
- Site Reference ID/Investigator# 47111
-
Tokyo, Япония
- Site Reference ID/Investigator# 47112
-
Tokyo, Япония
- Site Reference ID/Investigator# 47116
-
Tokyo, Япония
- Site Reference ID/Investigator# 47117
-
Tokyo, Япония
- Site Reference ID/Investigator# 47161
-
Tokyo, Япония
- Site Reference ID/Investigator# 47164
-
Toyama, Япония
- Site Reference ID/Investigator# 47165
-
Toyoake, Япония
- Site Reference ID/Investigator# 47167
-
Yamagata-shi, Япония
- Site Reference ID/Investigator# 47105
-
Yamatotakada, Япония
- Site Reference ID/Investigator# 47175
-
Yokohama, Япония
- Site Reference ID/Investigator# 47120
-
Yokohama-shi, Япония
- Site Reference ID/Investigator# 47121
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Diagnosis of ulcerative colitis for greater than 90 days prior to Baseline.
- Active ulcerative colitis with a Mayo Score of 6-12 points at Baseline and endoscopy subscore of 2-3 during the Screening Period, despite concurrent treatment with at least one of the following (oral corticosteroids or immunosuppressants or both as defined below):
- Stable oral corticosteroid dose (prednisolone dose of ≥ 20 mg/day or equivalent) for at least 14 days prior to Baseline or stable oral corticosteroid dose (prednisolone of 5 to less than 20 mg/day) for at least 40 days prior to Baseline. And/or
- At least a consecutive 90-day course of azathioprine or 6-mercaptopurine (6-MP) prior to Baseline, with a dose of azathioprine ≥ 50 mg/day or 6-MP ≥ 30 mg/day, or a dose that was the highest tolerated by the patient.
Exclusion Criteria:
- History of subtotal colectomy with ileorectostomy or colectomy with ileoanal pouch, Koch pouch, or ileostomy for ulcerative colitis or was planning bowel surgery.
- Patients with disease limited to the rectum.
- Indeterminate colitis and/or Crohn's disease.
- Received any biological therapy (including infliximab) in the past.
- History of tuberculosis or malignancy.
- Pregnant women.
- Patients with positive C. difficile stool assay at Screening.
- Current diagnosis of fulminant colitis and/or toxic megacolon.
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Двойной
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
---|---|
Плацебо Компаратор: Placebo
Participants received placebo subcutaneous injections every 2 weeks for 52 weeks.
From Week 8, participants with an inadequate response could switch to rescue therapy, where they initially received adalimumab 160 mg, 80 mg 2 weeks later, and then 40 mg every other week.
Participants who completed the 52-week double-blind period received open-label adalimumab 40 mg every other week, with the possibility to escalate to 80 mg every other week, until drug approval.
|
Другие имена:
|
Экспериментальный: Adalimumab 80 mg/40 mg
Participants received adalimumab 80 mg on Day 1, 40 mg at Week 2 and 40 mg every other week from Week 4 to Week 50, via subcutaneous injection.
From Week 8, participants with an inadequate response could switch to rescue therapy, where they received adalimumab 40 mg every other week.
Participants who completed the 52-week double-blind period received open-label adalimumab 40 mg every other week, with the possibility to escalate to 80 mg every other week, until drug approval.
|
Другие имена:
|
Экспериментальный: Adalimumab 160 mg/80 mg
Participants received adalimumab 160 mg on Day 1, 80 mg at Week 2 and 40 mg every other week from Week 4 to Week 50, via subcutaneous injection.
From Week 8, participants with an inadequate response could switch to rescue therapy, where they received adalimumab 40 mg every other week.
Participants who completed the 52-week double-blind period received open-label adalimumab 40 mg every other week, with the possibility to escalate to 80 mg every other week, until drug approval.
|
Другие имена:
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
---|---|---|
Percentage of Participants With Clinical Remission at 8 Weeks
Временное ограничение: Week 8
|
Clinical remission was defined as a Mayo score ≤ 2 with no individual subscore > 1. The Mayo score is a composite score of ulcerative colitis disease activity calculated as the sum of four subscores:
The total Mayo score ranges from 0 to 12 points, with higher scores representing more severe disease. |
Week 8
|
Percentage of Participants With Clinical Remission at 52 Weeks
Временное ограничение: Week 52
|
Clinical remission was defined as a Mayo score ≤ 2 with no individual subscore > 1. The Mayo score is a composite score of ulcerative colitis disease activity calculated as the sum of four subscores:
The total Mayo score ranges from 0 to 12 points, with higher scores representing more severe disease. |
Week 52
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
---|---|---|
Percentage of Participants With Clinical Remission at 8, 32, and 52 Weeks
Временное ограничение: Weeks 8, 32, and 52
|
Clinical remission was defined as a Mayo score ≤ 2 with no individual subscore > 1. The Mayo score is a composite score of ulcerative colitis disease activity calculated as the sum of four subscores:
The total Mayo score ranges from 0 to 12 points, with higher scores representing more severe disease. |
Weeks 8, 32, and 52
|
Percentage of Participants With a Clinical Response
Временное ограничение: Baseline and Weeks 8, 32, and 52
|
A clinical response was defined as a decrease in Mayo score of ≥ 3 points and ≥ 30% from Baseline PLUS a decrease in the Rectal Bleeding Subscore (RBS) ≥ 1 or an absolute RBS of 0 or 1. The Mayo score is a composite score of ulcerative colitis disease activity calculated as the sum of four subscores:
The total Mayo score ranges from 0 to 12 points, with higher scores representing more severe disease. |
Baseline and Weeks 8, 32, and 52
|
Percentage of Participants With Mucosal Healing
Временное ограничение: Weeks 8, 32, and 52
|
Mucosal healing was defined as an endoscopy subscore of ≤ 1 and was assessed using flexible sigmoidoscopy performed at Weeks 8, 32, and 52. The endoscopy subscore ranges from zero to three as follows: 0 = Normal or inactive disease, 1 = Mild disease (erythema, decreased vascular pattern, mild friability), 2 = Moderate disease (marked erythema, absent vascular pattern, friability, erosions), 3 = Severe disease (spontaneous bleeding, ulceration). |
Weeks 8, 32, and 52
|
Percentage of Participants With Rectal Bleeding Subscore Indicative of Mild Disease (≤ 1)
Временное ограничение: Weeks 8, 32, and 52
|
Rectal bleeding was assessed from the participant's diary, taking the worst score from the 3 days prior to each study visit. The rectal bleeding subscore ranges from zero to three, according to the following scale: 0 = no blood seen, 1 = streaks of blood with stool less than half the time, 2 = obvious blood with stool most of the time, 3 = blood alone passed. |
Weeks 8, 32, and 52
|
Percentage of Participants With Physician's Global Assessment Subscore Indicative of Mild Disease (≤ 1)
Временное ограничение: Weeks 8, 32, and 52
|
The Physician's Global Assessment Subscore acknowledges the three other subscores (Stool Frequency, Rectal Bleeding, and Endoscopy), the participant's daily record of abdominal discomfort and functional assessment, and other observations such as physical findings and the participant's performance status. Possible scores range from zero to three as follows: 0 = Normal (other subscores are 0), 1 = Mild disease (other subscores are mostly 1), 2 = Moderate disease (other subscores are 1 to 2), 3 = Severe disease (other subscores are 2 to 3). |
Weeks 8, 32, and 52
|
Percentage of Participants With Stool Frequency Subscore Indicative of Mild Disease (≤ 1)
Временное ограничение: Weeks 8, 32, and 52
|
Stool frequency was assessed from the participant's diary, taking the worst score from the 3 days prior to each study visit. The stool frequency subscore ranges from zero to three, according to the following scale: 0 = Normal number of stools for this participant, 1 = 1-2 stools more than normal, 2 = 3-4 stools more than normal, 3 = 5 or more stools more than normal. |
Weeks 8, 32, and 52
|
Percentage of Inflammatory Bowel Disease Questionnaire (IBDQ) Responders
Временное ограничение: Baseline and Weeks 8, 32, and 52
|
An inflammatory bowel disease questionnaire responder was defined as a participant with at least a 16-point increase from Baseline in total Inflammatory Bowel Disease Questionnaire (IBDQ) score.
The IBDQ is a 32-item questionnaire consisting of 4 dimensions: bowel-related symptoms, systemic function, social function, and emotional status.
The responses to each question within each domain range from 1 (significant impairment) to 7 (no impairment), with the total score ranging from 32 (very poor) to 224 (perfect health-related quality of life).
|
Baseline and Weeks 8, 32, and 52
|
Number of Participants With Adverse Events up to Week 8
Временное ограничение: 8 weeks
|
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related. A serious adverse event is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. For more details on adverse events please see the Adverse Event section below. |
8 weeks
|
Number of Participants With Adverse Events up to Week 52
Временное ограничение: 52 weeks
|
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related. A serious adverse event is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. For more details on adverse events please see the Adverse Event section below. |
52 weeks
|
Number of Participants With Adverse Events During the Adalimumab Treatment Period
Временное ограничение: 221 weeks
|
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related. A serious adverse event is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. For more details on adverse events please see the Adverse Event section below. |
221 weeks
|
Соавторы и исследователи
Спонсор
Соавторы
Следователи
- Директор по исследованиям: Morio Ozawa, MS, AbbVie GK.
Публикации и полезные ссылки
Полезные ссылки
Даты записи исследования
Изучение основных дат
Начало исследования
Первичное завершение (Действительный)
Завершение исследования (Действительный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Оценивать)
Обновления учебных записей
Последнее опубликованное обновление (Оценивать)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- M10-447
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .
Клинические исследования плацебо
-
University of FloridaЗавершенныйАпноэ сна, обструктивное | ХрапСоединенные Штаты
-
Centre Hospitalier Universitaire de Saint EtienneЗавершенный
-
PfizerЗавершенныйАтопический дерматитКитай, Япония, Корея, Республика
-
Tasly Pharmaceutical Group Co., LtdНеизвестныйСиндром раздраженного кишечника с диареейКитай
-
Guang'anmen Hospital of China Academy of Chinese...НеизвестныйИшемическая болезнь сердца | Нестабильная стенокардия | Синдром застоя кровиКитай
-
University Hospital, Clermont-FerrandРекрутингОральный мукозитФранция
-
Henan University of Traditional Chinese MedicineJiangsu Province Hospital of Traditional Chinese MedicineНеизвестныйХроническое обструктивное заболевание легкихКитай
-
Universidad Francisco de VitoriaЗавершенныйПищевая добавка | Спортивная производительностьИспания
-
TakedaЗавершенныйХроническая бессонницаСоединенные Штаты
-
TakedaЗавершенныйХроническая бессонница